Download PDF
TumorDiagnostik & Therapie 2001; 22(1): 1-13
DOI: 10.1055/s-2001-12745
ÜBERSICHT/REVIEW
© Georg Thieme Verlag Stuttgart · New York

Die Bedeutung von Peptidhormonen des Magen-Darm-Trakts
für das Wachstum von humanen gastrointestinalen Tumoren[*]

The Role of Gastrointestinal Hormones for the Growth of Gastrointestinal MalignanciesCh. Lersch, J. Erdmann, V. Schusdziarra
  • II. Medizinische Klinik und Poliklinik der Technischen Universität München, Klinikum rechts der Isar
Further Information

Publication History

Publication Date:
31 December 2001 (online)

Also available at
    Permissions and Reprints

Zusammenfassung.

Rezeptoren für Peptidhormone wurden auf Tumoren und Tumorzelllinien des Gastrointestinaltrakts nachgewiesen. In der Übersicht werden Daten über Peptide, für deren Agonisten bzw. Antagonisten Wirkungen bei humanen Tumoren gezeigt wurden, zusammenfassend dargestellt. Gastrin-Antagonisten können das Wachstum von Pankreas- und Kolonkarzinomzelllinien in vitro und in Nacktmäusen hemmen, nicht dagegen bisher bei Patienten mit Pankreas- und Magenkarzinomen. Eine Rolle des Gastrins bei der Karzinogenese des Magen- und Kolonkarzinoms wird diskutiert. Weder Cholezystokinin-Antagonisten noch -agonisten konnten das Wachstum von Pankreaskarzinomen bei Patienten hemmen. Über Neurotensin-Rezeptoren kann in vitro das Wachstum von Kolon- und Pankreaszelllinien gesteigert werden. Vasoaktives Intestinales Peptid (VIP) beeinflusst das Wachstum von humanen gastrointestinalen Tumoren unterschiedlich. Das Peptid YY kann das Wachstum humaner Pankreas- und Kolonkarzinomzelllinien hemmen. Der Einsatz von Somatostatin und Analoga bei neuronendokrinen Tumoren ist etabliert. Auch bei Kolonkarzinomen und deren Vorläufern sowie beim hepatozellulären Karzinom könnten diese Substanzen wirksam sein.

The Role of Gastrointestinal Hormones for the Growth of Gastrointestinal Malignancies.

Receptors for regulatory gut/brain peptides are expressed on gastrointestinal tumors and tumor cell lines. This review summarizes data on those agonists and antagonists of peptides which effect the growth of human gastrointestinal tumors. Growth of pancreatic and colon carcinomas is retarded by gastrin and its agonists in vitro and in nude mice but not in men. A significant role of gastrin in human colorectal and stomach cancers has recently been discussed. Cholecystokinin and its agonists/antagonists did not stop the growth of pancreatic carcinomas in patients. In vitro growth of pancreatic and colon cancer cell lines could be stimulated via receptors for neurotensin. Vasoactive intestinal peptide (VIP) has ambivalent effects on the growth of gastrointestinal tumors. Peptide YY decreases the growth of human pancreatic and colon cancer cell lines. Somatostatin and its agonists are successfully used for therapy of neuroendocrine tumors. They also could be effective in therapy of colon and hepatocellular carcinomas.

Schlüsselwörter:

Gastrointestinale Peptidhormone - Agonisten - Antagonisten - Gastrointestinale Tumoren

Key Words:

Gastrointestinal peptides - Agonists - Antagonists - Gastrointestinal malignancies

1 Diese Arbeit wird von der Sander Stiftung unterstützt.

Literatur

  • 1 Beatson G T. On the treatment of inoperable cases of carcinoma of the mamma: suggestion for a new method of treatment, with illustrative cases.  Lancet. 1896;  2 104-107
    PubMedGoogle Scholar
  • 2 El Salhy M, Sandstrom O. How age changes the content of neuroendocrine peptides in the murine gastrointestinal tract.  Gerontology. 1999;  45 (1) 17-22
    CrossrefPubMedGoogle Scholar
  • 3 Lillemoe K D. Hormonal therapy for gastrointestinal cancer. Editorial.  Annals of Surgery. 1996;  123 (1) 12-13
    PubMedGoogle Scholar
  • 4 Rehfeld J F, van Solinge W W. The tumor biology of gastrin and cholecystokinin.  Adv Cancer Res. 1994;  63 295-347
    PubMedGoogle Scholar
  • 5 Caplin M, Khan K, Savage K, Rode J, Varro A, Michaeli D, Grimes S, Brett B, Pounder R, Dhillon A. Expression and processing of gastrin in hepatocellular carcinoma, fibrolamellar carcinoma and cholangiocarcinoma.  J Hepatol. 1999;  30 (3) 519-526
    CrossrefPubMedGoogle Scholar
  • 6 de Weerth A, von Schrenck T, Lohr M, Mirau S, Greten H, Kalthoff H. Human pancreatic cancer cell lines express the CCKB receptor.  Hepatogastroenterology. 1999;  46 (25) 472-478
    PubMedGoogle Scholar
  • 7 Schmidt B F, Hernandez L, Rouzer C, Czerwinski G, Chmurny G, Michejda C J. Peptide-linked 1,3-dialkyl-3-acyltriazenes: gastrin receptor directed antineoplastic alkylating agents.  J Med Chem. 1994;  37 (22) 3812-3818
    CrossrefPubMedGoogle Scholar
  • 8 Frucht H, Gazdar A F, Park J A, Oie H, Jensen R T. Characterization of functional receptors for gastrointestial hormones on human colon cancer cells.  Cancer Res. 1992;  52 (5) 1114-1122
    PubMedGoogle Scholar
  • 9 Clerc P, Dufresne M, Saillan C, Chastre E, Andre T, Escrieut C, Kennedy K, Vaysse N, Gespach C, Fourmy D. Differential expression of the CCK-A and CCK-B/gastrin receptor genes in human cancers of the esophagus, stomach and colon.  Int J Cancer. 1997;  72 (6) 931-933
    CrossrefPubMedGoogle Scholar
  • 10 McWilliams D F, Watson S A, Crosbee D M, Michaeli D, Seth R. Coexpression of gastrin and gastrin receptors (CCK-B and delta CCK-B) in gastrointestinal tumour cell lines.  Gut. 1998;  42 (6) 795-798
    PubMedGoogle Scholar
  • 11 Smith A M, Watson S A. Gastrin and gastrin receptor activation: an early event in the adenoma-carcinoma sequence.  Gut. 2000;  47 820-824
    CrossrefPubMedGoogle Scholar
  • 12 Upp J, Singh P, Townsend C M, Thompson J C. Clinical significance of gastrin receptors in human colon cancers.  Cancer Res. 1989;  49 488-492
    PubMedGoogle Scholar
  • 13 Johnson L R, Aures D, Hakanson R. Effect of gastrin on the in vivo incorporation of 14C-leucine into proteins of the digestive tract.  Proc Soc Exp Biol Med. 1969;  132 996-998
    PubMedGoogle Scholar
  • 14 Smith J P, Solomon T E. Effects of gastrin, proglumide, and somatostatin on growth of human colon cancer.  Gastroenterology. 1988;  95 1541-1548
    PubMedGoogle Scholar
  • 15 Seitz J F, Giovannini M, Gouvernet J, Gauthier A P. Elevated gastrin levels in patients with colon cancer or adenomatous polyps.  Dig Dis Sci. 1989;  34 171-174
    CrossrefPubMedGoogle Scholar
  • 16 Wong K, Beardshall K, Waters C M, Calam J, Poston G J. Postprandial hypergastrinaemia in patients with colorectal cancer.  Gut. 1991;  32 1352-1354
    PubMedGoogle Scholar
  • 17 Payer J, Huorka M, Duris I, Ondrrejka P, Kratochvilova H Ilkova M, Holeczy P. Circadian rhythmicity of plasma somatostatin, gastrin and cortisol in colon cancer patients.  Hepatogastroenterology. 1997;  44 (13) 72-77
    PubMedGoogle Scholar
  • 18 Renga M, Brandi G, Paganelli G M, Calabrese C, Papa S, Tosti A, Tomassetti P, Miglioli M, Biasco G. Rectal cell proliferation and colon cancer risk in patients with hypergastrinaemia.  Gut. 1997;  41 (3) 330-332
    PubMedGoogle Scholar
  • 19 Thorburn C M, Friedman G D, Dickinson C J, Vogelman J H, Orentreich N, Parsonnet J. Gastrin and colorectal cancer: a prospective study.  Gastroenterology. 1998;  115 (2) 275-280
    PubMedGoogle Scholar
  • 20 Niv Y, Heizelracht N, Lamprecht S A, Sperber A D, Fraser G M, Schwartz B. Gastrin levels in colorectal cancer.  Isr J Med Sci. 1997;  33 (3) 186-189
    PubMedGoogle Scholar
  • 21 Fontanesi B V, Boris B, Delcio M, Manoukian F N. Gastrin levels in patients with colorectal cancer.  Hepatogastroenterology. 1997;  44 (16) 1082-1084
    PubMedGoogle Scholar
  • 22 Chu M, Rehfeld J F, Borch K. Effects of gastric fundectomy and antrectomy on the colonic mucosa in the hamster.  Digestion. 1992;  53 23-34
    PubMedGoogle Scholar
  • 23 Chu M, Rehfeld J F, Borch K. Colonic mucosal proliferation after pancreaticobiliary diversion in the hamster.  Dig Dis Sci. 1993;  38 1978-1984
    CrossrefPubMedGoogle Scholar
  • 24 Hakanson R, Blom H, Carlsson E, Larsson H, Ryberg B, Sundler F. Hypergastrinaemia produces trophic effects in stomach, but not in pancreas and intestines.  Regul Pept. 1986;  13 (3-4) 225-233
    CrossrefPubMedGoogle Scholar
  • 25 Hakanson R, Axelson J, Ekman R, Sundler F. Hypergastrinaemia evoked by omeprazole stimulates growth of gastric mucosa but not of pancreas or intestines, in guinea pig and chicken.  Regul Pept. 1988;  23 105-115
    CrossrefPubMedGoogle Scholar
  • 26 Chen D, Destree M, Hakanson R, Willems G. Endogenous hypergastrinaemia does not promote growth of colonic mucosa or of a transplanted colon adenocarcinoma in rats.  Eur J Gastroenterol Hepatol. 1998;  10 (4) 293-299
    PubMedGoogle Scholar
  • 27 Koh T J, Dockray G J, Varro A, Cahill R J, Dangler C A, Fox J G, Wang T C. Overexpression of glycine-extended gastrin in transgenic mice results in increased colonic proliferation.  J Clin Invest. 1999;  103 (8) 1119-1126
    PubMedGoogle Scholar
  • 28 Graffner H, Singh G, Chaudry I, Milsom J W. Omeprazol-induced hypergastrinemia does not influence growth of colon carcinoma.  Dig Dis Sci. 1992;  37 485-489
    CrossrefPubMedGoogle Scholar
  • 29 Konturek P C, Bielanski W, Bobrzynski A, Hahn E G, Konturek S J. Gastric mucosal expression and luminal release of growth factors in gastric carcinoma and duodenal ulcer patients before and after eradication of Helicobacter pylori.  J Physiol Pharmacol. 1997;  48 (3) 375-382
    PubMedGoogle Scholar
  • 30 Konturek P C, Konturek S J, Bielanski W, Karczewska E, Pierzchalski P. Role of gastrin in gastric cancerogenesis in Helicobacter pylori infected humans.  J Physiol Pharmacol. 1999;  50 (5) 857-863
    PubMedGoogle Scholar
  • 31 Wang T C, Dangler C A, Chen D, Goldenring J R, Koh T, Raychowdhury R, Coffey R J, Ito S, Varro A, Dockray G J, Fox J G. Synergistic interaction between hypergastrinemia and Helicobacter infection in a mouse model of gastric cancer.  Gastroenterology. 2000;  118 (1) 36-47
    PubMedGoogle Scholar
  • 32 Breuer-Katschinski B, Nemes K, Marr A, Rump B, Leiendecker B, Breuer N, Goebell H. Helicobacter pylori and the risk of colonic adenomas. Colorectal Adenoma Study Group.  Digestion. 1999;  60 (3) 210-215
    CrossrefPubMedGoogle Scholar
  • 33 Lamberts R, Wartenberg T, Creutzfeldt W. Role of circulating gastrin in colorectal adenomas and carcinomas.  Digestion. 1999;  60 (2) 101-109
    CrossrefPubMedGoogle Scholar
  • 34 Watson S A, Clarke P A, Smith A M, Varro A, Michaeli D, Grimes S, Caplin M, Hardcastle J D. Expression of CCKB/gastrin receptor isoforms in gastro-intestinal tumour cells.  Int J Cancer. 1998;  77 (4) 572-577
    CrossrefPubMedGoogle Scholar
  • 35 Seva C, Dickinson C J, Yamada T. Growth-promoting effects of glycine-extended progastrin.  Science. 1994;  265 410-412
    PubMedGoogle Scholar
  • 36 van Solinge W W, Nielsen F C, Friis-Hansen L, Falkmer U G, Rehfeld J F. Expression but incomplete maturation of progastrin in colorectal carcinomas.  Gastroenterology. 1993;  104 (4) 1099-1107
    PubMedGoogle Scholar
  • 37 Bestervelt L, Barr B, Dethloff L. Divergent proliferative responses to a gastrin receptor ligand in synchronized and unsynchronized rat pancreatic AR42J tumour cells.  Cell Signal. 2000;  12 (1) 53-61
    CrossrefPubMedGoogle Scholar
  • 38 Stepan V M, Sawada M, Todisco A, Dickinson C J. Glycine-extended gastrin exerts growth-promoting effects on human colon cancer cells.  Mol Med. 1999;  5 (3) 147-159
    PubMedGoogle Scholar
  • 39 Johnson L R, Aures D, Hakanson R. Effect of gastrin on the in vivo incorporation of 14C-leucine into proteins of the digestive tract.  Proc Soc Exp Biol Med. 1969;  132 996-998
    PubMedGoogle Scholar
  • 40 Artru P, Attoub S, Levasseur S, Lewin M J, Bado A. Gastrin-17 and G17-gly induce proliferation of LoVo cells through the CCK B/ gastrin receptor.  Gastroenterol Clin Biol. 1998;  22 (6-7) 607-612
    PubMedGoogle Scholar
  • 41 Kelly A, Hollande F, Shulkes A, Baldwin G S. Expression of progastrin-derived peptides and gastrin receptors in a panel of gastrointestinal carcinoma cell lines.  J Gastroenterol Hepatol. 1998;  13 (2) 208-214
    PubMedGoogle Scholar
  • 42 Bold R J, Ishizuka J, Townsend C M, Thompson J C. Gastrin stimulates growth of human colon cancer cells via a receptor other than CCK-A or CCK-B.  Biochem Biophys Res Commun. 1994;  202 (3) 1222-1226
    CrossrefPubMedGoogle Scholar
  • 43 Baldwin G S. Antiproliferative gastrin/cholecystokinin receptor antagonists target 78-kDA gastrin-binding protein.  Proc Natl Acad Sci USA. 1994;  91 3605-3609
    PubMedGoogle Scholar
  • 44 Biagini P, Monges G, Vuaroqueaux V, Parriaux D, Cantaloube J F, De Micco P. The human gastrin/cholecystokinin receptors: type B and C expression in colonic tumors and cell lines.  Life Sci. 1997;  61 (10) 1009-1018
    CrossrefPubMedGoogle Scholar
  • 45 Goetze J P, Nielsen F C, Burcharth F, Rehfeld J F. Closing the gastrin loop in pancreatic carcinoma. Coexpression of gastrin and its receptor in solid human pancreatic adenocarcinoma.  Cancer. 2000;  88 2487-2494
    CrossrefPubMedGoogle Scholar
  • 46 Singh P, Dai B, Wu H, Owlia A. Role of autocrine and endocrine gastrin-like peptides in colonic carcinogenesis.  Curr Opin Gastroenterol. 2000;  16 68-77
    CrossrefPubMedGoogle Scholar
  • 47 Nakata H, Wang S L, Chung D C, Westwick J K, Tillotson L G. Oncogenic ras induces gastrin gene expression in colon cancer.  Gastroenterology. 1998;  115 (5) 1144-1153
    PubMedGoogle Scholar
  • 48 Watson S A, Cliffort T, Sykes R E, Robinson E, Steele R JC. Gastrin sensitivity of primary human colorectal cancer: the effect of receptor antagonism.  Eur J Cancer. 1995;  31A 2086-2092
    PubMedGoogle Scholar
  • 49 Bold R J, Ishizuka J, Townsend C M, Thompson J C. Gastrin stimulates growth of human colon cancer cells via a receptor other than CCK-A or CCK-B.  Biochem Biophys Res Commun. 1994;  202 (3) 1222-1226
    CrossrefPubMedGoogle Scholar
  • 50 Mauss S, Niederau C, Hengels K J. Effect of gastrin, proglumide, loxiglumide and L-365,260 on growth of human colon carcinoma cells.  Anticancer Res. 1994;  14 215-220
    PubMedGoogle Scholar
  • 51 Romani R, Howes L G, Morris D L. Gastrin receptor antagonist CI-998 inhibits growth of human colon cancer in vivo and in vitro.  Aust N Z J Surg. 1996;  66 235-237
    PubMedGoogle Scholar
  • 52 Fisher W E, Muscarella P, Boros L G, Schirmer W J. Gastrointestinal hormones as potential adjuvant treatment of exocrine pancreatic adenocarcinoma.  Int J Pancreatol. 1998;  24 (3) 169-180
    PubMedGoogle Scholar
  • 53 Ohlsson B, Fredang N, Axelson J. The effect of bombesin, cholecystokinin, gastrin, and their antagonists on proliferation of pancreatic cancer cell lines.  Scand J Gastroenterol. 1999;  34 (12) 1224-1229
    CrossrefPubMedGoogle Scholar
  • 54 Monstein H J, Ohlsson B, Rehfeld J F, Axelson J. Expression of cholecystokinin-B receptor and gastrin mRNA in human pancreatic cancer cell lines.  Digestion. 2000;  61 308
    PubMedGoogle Scholar
  • 55 Vidgren V, Varis A, Kokkola A, Monni O, Puolakkainen P, Nordling S, Forozan F, Kallioniemi A, Vakkari M L, Kivilaakso E, Knuutila S. Concomitant gastrin and ERBB2 gene amplifications at 17q12-q21 in the intestinal type of gastric cancer.  Genes Chromosomes Cancer. 1999;  24 (1) 24-29
    CrossrefPubMedGoogle Scholar
  • 56 Liu X, Zhang Z, Yang L, Qiang O. Regulative effects pentagastrin and somatostatin on growth of human gastric cancer cells in vitro.  Hua Hsi I Ko Ta Hsueh Hsueh Pao. 1998;  29 (3) 292-294
    PubMedGoogle Scholar
  • 57 Iwase K, Evers B M, Hellmich M R, Guo Y S, Higashide S, Kim H J, Townsend C M. Regulation of growth of human gastric cancer by gastrin and glycine-extended progastrin.  Gastroenterology. 1997;  113 (3) 782-790
    PubMedGoogle Scholar
  • 58 Chu M, Nielsen F C, Franzen L, Rehfeld J F, Holst J J, Borch K. Effect of endogenous hypergastrinemia on gastrin receptor expressing human colon carcinoma transplanted to athymic rats.  Gastroenterology. 1995;  109 (5) 1415-1420
    PubMedGoogle Scholar
  • 59 Vidal C, Rauly I, Zeggari M, Delesque N, Esteve J P, Saint-Laurent N, Vaysee N, Susini C. Up-regulation of somatostatin receptors by epidermal growth factor and gastrin in pancreatic cancer cells.  Mol Pharmacol. 1994;  46 (1) 97-104
    PubMedGoogle Scholar
  • 60 Bold R J, Ishizuka J, Townsend C M, Thompson J C. Gastrin stimulates growth of human colon cancer cells via a receptor other than CCK-A or CCK-B.  Biochem Biophys Res Commun. 1994;  202 (3) 1222-1226
    CrossrefPubMedGoogle Scholar
  • 61 Mauss S, Niederau C, Hengels K J. Effect of gastrin, proglumide, loxiglumide and L-365,260 on growth of human colon carcinoma cells.  Anticancer Res. 1994;  14 215-220
    PubMedGoogle Scholar
  • 62 Singh P, Reubi J C, Rajakumar G, Guo Y S, Prioux H, Chicone L. In vivo mitogenic effects of estradiol on colon cancers: role of gastrin and gastrin receptors.  J Steroid Biochem Mol Biol. 1993;  46 (1) 49-60
    CrossrefPubMedGoogle Scholar
  • 63 Smith J P, Solomon T E. Effects of gastrin, proglumide, and somatostatin on growth of human colon cancer.  Gastroenterology. 1988;  95 1541-1548
    PubMedGoogle Scholar
  • 64 Tatsuta M, Iishi H, Baba M, Nakaizumi A. Effect of tetragastrin on azaserine-induced carcinogenesis in rat pancreas.  Int J Cancer. 1990;  46 (3) 489-492
    PubMedGoogle Scholar
  • 65 Smith J P, Liu G, Soundararajan V, McLaughlin P J, Zagon I S. Identification and characterization of CCK-B/gastrin receptors in human pancreatic cancer cell lines.  Am J Physiol. 1994;  266 (1 Pt 2) R277-R283
    PubMedGoogle Scholar
  • 66 Karsenty L, Hajri A, Aprahamian M, Garaud J C, Doffoel M, Damge C. Inhibition of growth of a transplanted rat pancreatic acinar carcinoma with CCK-8.  Pancreas. 1993;  8 (2) 204-211
    PubMedGoogle Scholar
  • 67 Fontana M G, Donato F, Villanacci V, Ghirardi M, Moneghini D, Di-Betta E, Salerni B. Inhibitory effect of a gastrin receptor antagonist, CR2945, on 1,2-dimethylhydrazine-induced colorectal cancer in mice.  Eur Surg Res. 1999;  31 (5) 406-411
    CrossrefPubMedGoogle Scholar
  • 68 Litvak D A, Hellmich M R, Iwase K, Evers B M, Martinez J, Amblard M, Townsend C M. JMV1155: a novel inhibitor of glycine-extended progastrin-extended progastrin-mediated growth of a human colon cancer in vivo.  Anticancer Res. 1999;  19 (1A ) 45-49
    PubMedGoogle Scholar
  • 69 Watson S A, Michael D, Justin T A, Grimes S, Morris T M, Robinson G, Clarke P A, Hardcastle J D. Pre-clinical evaluation of the Gastrimmune immunogen alone and in combination with 5-fluorouracil/leucovorin in a rat colorectal cancer model.  Int J Cancer. 1998;  75 (6) 873-877
    CrossrefPubMedGoogle Scholar
  • 70 Watson S A, Morris T M, Varro A, Michaeli D, Smith A M. A comparison of the therapeutic effectiveness of gastrin neutralisation in two human gastric cancer models: relation to endocrine and autocrine/paracrine gastrin mediated growth.  Gut. 1999;  45 (6) 812-817
    PubMedGoogle Scholar
  • 71 Watson S A, Michaeli D, Morris T M, Clarke P, Varro A, Griffin N, Smith A, Justin T, Hardcastle J D. Antibodies raised by gastrimmune inhibit the spontaneous metastasis of a human colorectal Tumour, AP5LV.  Eur J Cancer. 1999;  35 (8) 1286-1291
    CrossrefPubMedGoogle Scholar
  • 72 Smith J P, Verderame M F, Zagon I S. Antisense oligonucleotides to gastrin inhibit growth of human pancreatic cancer.  Cancer Lett. 1999;  135 (1) 107-112
    PubMedGoogle Scholar
  • 73 Harrison J D, Jones J A, Morris D L. The effect of the gastrin receptor antagonist proglumide on survival in gastric carcinoma.  Cancer. 1990;  66 1449-1452
    PubMedGoogle Scholar
  • 74 Penman I D, McColl K E. Gastrin and colorectal cancer: where now? [see comments].  Eur J Gastroenterol Hepatol. 1998;  10 (4) 285-288 , Comment in: Eur J Gastroenterol Hepatol 1998; 10 (4): 293-298
    PubMedGoogle Scholar
  • 75 Abbruzzese J L, Gholson C F, Daugherty K, Larson E, DuBrow R, Berlin R, Levin B. A pilot clinical trial of the cholecystokinin receptor antagonist MK-329 in patients with advanced pancreatic cancer.  Pancreas. 1992;  7 (2) 165-171
    PubMedGoogle Scholar
  • 76 Militello C, Sperti C, Di Prima F, Pedrazzoli S. Clinical evaluation and safety of loxiglumide (CCK-A receptor antagonist) in nonresectable pancreatic cancer patients. Italian Pancreatic Cancer Study Group.  Pancreas. 1997;  14 (3) 222-228
    PubMedGoogle Scholar
  • 77 Axelson J, Ihse I, Hakanson R. Pancreatic cancer: the role of cholecystokinin?.  Scand J Gastroenterol. 1992;  27 993-998
    PubMedGoogle Scholar
  • 78 Niederau C, Luthen R, Heintges T. Effects of CCK on pancreatic function and morphology.  Ann NY Acad Sci. 1994;  713 180-198
    PubMedGoogle Scholar
  • 79 de Weerth A, von Schrenck T, Lohr M, Mirau S, Greten H, Kalthoff H. Human pancreatic cancer cell lines express the CCKB receptor.  Hepatogastroenterology. 1999;  46 (25) 472-478
    PubMedGoogle Scholar
  • 80 Kaufmann R, Schafberg H, Rudroff C, Henklein P, Nowak G. Cholecystokinin B-type receptor signaling is involved in human pancreatic cancer cell growth.  Neuropeptides. 1997;  31 (6) 573-583
    CrossrefPubMedGoogle Scholar
  • 81 Weinberg D S, Ruggeri B, Barber M T, Biswas S, Miknyocki S, Waldman S A. Cholecystokinin A and B receptors are differentially expressed in normal pancreas and pancreatic adenocarcinoma.  J Clin Invest. 1997;  100 (3) 597-603
    PubMedGoogle Scholar
  • 82 Weinberg D S, So C, Ruggeri B, Biswas S, Barber M, Waldman S. Human cholecystokinin-A receptor is not an oncofetal protein.  Dig Dis Sci. 2000;  45 (3) 538-543
    CrossrefPubMedGoogle Scholar
  • 83 Clerc P, Dufresne M, Saillan C, Chastre E, Andre T, Escrieut C, Kennedy K, Vaysee N, Gespach C, Fourmy D. Differential expression of the CCK-A and CCK-B/gastrin receptor genes in human cancers of the esophagus, stomach and colon.  Int J Cancer. 1997;  72 (6) 931-936
    CrossrefPubMedGoogle Scholar
  • 84 Smith J P, Verderame M F, Zagon I S. Antisense oligonucleotides to gastrin inhibit growth of human pancreatic cancer.  Cancer Lett. 1999;  135 (1) 107-112
    PubMedGoogle Scholar
  • 85 Reubi J C, Waser B, Schmassmann A, Laissue J A. Receptor autoradiographic evaluation of cholecystokinin, neurotensin, somatostatin and vasoactive intestinal peptide receptors in gastro-intestinal adenocarcinoma samples: where are they really located?.  Int J Cancer. 1999;  81 376-386
    CrossrefPubMedGoogle Scholar
  • 86 Upp  J, Singh P, Townsend  C M, Thompson J C. Clinical significance of gastrin receptors in human colon cancers.  Cancer Res. 1989;  49 488-492
    PubMedGoogle Scholar
  • 87 Estival A, Clemente F, Ribet A. Adenocarcinoma of the human exocrine pancreas: presence of secretin and caerulein receptors.  Biochem Biophys Res Commun. 1981;  102 1336-1341
    CrossrefPubMedGoogle Scholar
  • 88 Reubi J C, Waser B, Schmassmann A, Laissue J A. Receptor autoradiographic evaluation of cholecystokinin, neurotensin, somatostatin and vasoactive intestinal peptide receptors in gastro-intestinal adenocarcinoma samples: where are they really located?.  Int J Cancer. 1999;  81 376-386
    CrossrefPubMedGoogle Scholar
  • 89 Ferrara C, Gress T, Müller-Pillasch F. Proto-oncogene jun expression is induced in the rat pancreas by cerulein infusion.  Digestion. 1995;  56 283
    PubMedGoogle Scholar
  • 90 Tateishi K, Funakoshi A, Misumi Y, Matsuoka Y. Jun and MAP kinases are activated by cholecystokinin in the pancreatic carcinoma cell line KP-1N.  Pancreas. 1998;  16 (4) 499-504
    PubMedGoogle Scholar
  • 91 Heald E B, Kramer S T, Smith J P. Trophic effects of unsulfated cholecystokinin on mouse pancreas and human pancreatic cancer.  Pancreas. 1992;  7 530-535
    PubMedGoogle Scholar
  • 92 Kobori O, Vuillot M T, Martin F. Growth responses of rat stomach cancer cells to gastro-entero-pancreatic hormones.  Int J Cancer. 1982;  30 65-67
    PubMedGoogle Scholar
  • 93 Smith J P, Rickabaugh C A, McLaughlin P J, Zagon I S. Cholecystokinin receptors and PANC-1 human pancreatic cancer cells.  Am J Physiol. 1993;  265 (1 Pt 1) G149-G155
    PubMedGoogle Scholar
  • 94 Swift I R, Smith J P. Cholecystokinin analog, JMV-180, stimulates growth of human pancreatic cancer.  Dig Dis Sci. 1994;  39 1007-1013
    PubMedGoogle Scholar
  • 95 Edwards B F, Redding T W, Schally A V. The effect of gastrointestinal hormones on the incorporation of tritiated thymidine in the pancreatic adenocarcinoma cell line (WD PaCa).  Int J Pancreatol. 1989;  5 191-201
    PubMedGoogle Scholar
  • 96 Hirata M, Tsuchida A, Iwao T, Sasaki T, Matsubara K, Yamamoto S, Morinaka K, Kawasaki Y, Fujimoto Y, Inoue H, Kariya K, Kajiyama G. Cholecystokinin regulates the invasiveness of human pancreatic cancer cell lines via protein kinase C pathway.  Int J Oncol. 1999;  14 (6) 1129-1135
    PubMedGoogle Scholar
  • 97 Ohlsson B, Fredang N, Axelson J. The effect of bombesin, cholecystokinin, gastrin, and their antagonists on proliferation of pancreatic cancer cell lines.  Scand J Gastroenterol. 1999;  34 (12) 1224-1229
    CrossrefPubMedGoogle Scholar
  • 98 Smith J P, Kramer S, Bagheri S. Effects of a high-fat diet and L364,718 on growth of human pancreas cancer.  Dig Dis Sci. 1990;  35 726-732
    CrossrefPubMedGoogle Scholar
  • 99 Detjen K, Fenrich M C, Logsdon C D. Transfected cholecystokinin receptors mediate growth inhibitory effects on human pancreatic cancer cell lines.  Gastroenterology. 1997;  112 952-959
    PubMedGoogle Scholar
  • 100 Mandair K K, Towner P, Stamford I F, Morris J D, Harper E, Benjamin I S, Tavares I A. Cholecystokinin receptors in human pancreatic cancer cell lines.  Eur J Cancer. 1998;  34 (9) 1455-1459
    CrossrefPubMedGoogle Scholar
  • 101 Smith J P, Solomon T E, Bagheri S, Kramer S. Cholecystokinin stimulates growth of human pancreatic adenocarcinoma SW-1990.  Dig Dis Sci. 1990;  35 1377-1384
    CrossrefPubMedGoogle Scholar
  • 102 Spindel E R, Giladi E, Segerson T P, Nagalla S. Bombesin-like peptides: of ligands and receptors.  Recent Progress Horm Res. 1993;  48 365-391
    PubMedGoogle Scholar
  • 103 Johnson L R, Aures D, Hakanson R. Effect of gastrin on the in vivo incorporation of 14C-leucine into proteins of the digestive tract.  Proc Soc Exp Biol. Med1969;  132 996-998
    PubMedGoogle Scholar
  • 104 Ferris H A, Carroll R E, Lorimer D L, Benya R V. Location and characterization of the human GRP receptor expressed by gastrointestinal epithelial cells.  Peptides. 1997;  18 (5) 663-672
    CrossrefPubMedGoogle Scholar
  • 105 Giladi E, Nagalla S R, Spindel E R. Molecular cloning and characterization of receptors for the mammalian bombesin-like peptides.  J Mol Neurosci. 1993;  4 41-54
    PubMedGoogle Scholar
  • 106 Preston S R, Woodhouse L F, Gokhale J, Miller G V, Primrose J N. Characterization of a bombesin/gastrin-releasing peptide receptor on a human gastric-cancer cell line.  Int J Cancer. 1994;  57 (5) 734-741
    PubMedGoogle Scholar
  • 107 Preston S R, Woodhouse L F, Jones Blackett S, Miller G V, Primrose J N. High-affinity binding sites for gastrin-releasing peptide on human colorectal cancer tissue but not uninvolved mucosa.  Br J Cancer. 1995;  71 1087-1089
    PubMedGoogle Scholar
  • 108 Williams B Y, Schonbrunn A. Bombesin receptors in a human duodenal tumor cell line: binding properties and function.  Cancer Res. 1994;  54 818-824
    PubMedGoogle Scholar
  • 109 Carroll R E, Carroll R, Benya R V. Characterization of gastrin-releasing peptide receptors aberrantly expressed by non-antral gastric adenocarcinomas.  Peptides. 1999;  20 (2) 229-237
    CrossrefPubMedGoogle Scholar
  • 110 Preston S R, Woodhouse L F, Jones Blackett S, Wyatt J I, Primrose J N. High affinity binding sites for gastrin releasing peptide on human gastric cancer and Menetriera's mucosa.  Cancer Res. 1993;  53 5090-5092
    PubMedGoogle Scholar
  • 111 Frucht H, Gazdar A F, Park J A, Oie H, Jensen R T. Characterization of functional receptors for gastrointestinal hormones on human colon cancer cells.  Cancer Res. 1992;  52 1114-1122
    PubMedGoogle Scholar
  • 112 Chave H S, Gough A C, Palmer K, Preston S R, Primrose J N. Bombesin family receptor and ligand gene expression in human colorectal cancer and normal mucosa.  Br J Cancer. 2000;  82 (1) 124-130
    CrossrefPubMedGoogle Scholar
  • 113 Carroll R E, Matkowskyi K A, Chakrabarti S, McDonald T J, Benya R V. Aberrant expression of gastrin-releasing peptide by well-differentiated colon cancers in humans.  Am J Physiol. 1999;  276 (3 Pt 1) G655-G665
    PubMedGoogle Scholar
  • 114 Chu M, Rehfeld J F, Borch K. Colonic mucosal proliferation after pancreaticobiliary diversion in the hamster.  Dig Dis Sci. 1993;  38 1978-1984
    CrossrefPubMedGoogle Scholar
  • 115 Saurin J C, Rouault J P, Abello J, Berger F, 'Remy L, Chayvialle J A. High gastrin releasing peptide receptor mRNA level is related to tumour dedifferentiation and lymphatic vessel invasion in human colon cancer.  Eur J Cancer. 1999;  35 (1) 125-132
    CrossrefPubMedGoogle Scholar
  • 116 Williams B Y, Schonbrunn A. Bombesin receptors in a human duodenal tumor cell line: binding properties and function.  Cancer Res. 1994;  54 818-824
    PubMedGoogle Scholar
  • 117 Bold R J, Kim H J, Ishizuka J, Townsend C M, Thompson J C. A human gastric cancer cell line possesses a functional receptor for gastrin-releasing peptide.  Cancer Invest. 1998;  16 (1) 12-17
    PubMedGoogle Scholar
  • 118 Bold R J, Ishizuka J, Townsend C M. Progress toward hormonal therapy of gastrointestinal cancer.  Ann Surg. 1996;  223 4-11
    CrossrefPubMedGoogle Scholar
  • 119 Draoui M, Chung P, Park M, Birrer M, Jakowlew S, Moody T W. Bombesin stimulates c-fos and c-jun mRNAs in small cell lung cancer.  Peptides. 1995;  16 (2) 289-292
    CrossrefPubMedGoogle Scholar
  • 120 DeMichele M A, Davis A L, Hunt J D, Landreneau R J, Siegfried J M. Expression of mRNA for three bombesin receptor subtypes in human bronchial epithelial cells.  Am J Respir Cell Mol Biol. 1994;  11 66-74
    PubMedGoogle Scholar
  • 121 Halmos G, Schally A V. Reduction in receptors for bombesin and epidermal growth factor in xenografts of human small-cell lung cancer after treatment with bombesin antagonist RC-3095.  Proc Natl Acad Sci USA. 1997;  94 956-960
    CrossrefPubMedGoogle Scholar
  • 122 Szepeshazi K, Schally A V, Halmos G, Lamharzi N, Groot K, Horvath J E. A single in vivo administration of bombesin antagonist RC-3095 reduces the levels and mRNA expression of epidermal growth factor receptors in MXT mouse mammary cancers.  Proc Natl Acad Sci USA. 1997;  94 (20) 10 913-10 918
    PubMedGoogle Scholar
  • 123 Ishizuka J, Townsend C M, Bold R J, Martinez J, Rodriguez M, Thompson J C. Effects of gastrin on 3',5'-cyclic adenosine monophosphate, intracellular calcium, and phosphatidylinositol hydrolysis in human colon cancer cells.  Cancer Res. 1994;  54 (8) 2129-2135
    PubMedGoogle Scholar
  • 124 Farre A, Ishizuka J, Gomez G, Parekh D, Koo J Y, Townsend C M, Thompson J C. Bombesin stimulates growth of colon cancer in mice and decreases their survival.  Surg Oncol. 1993;  2 (3) 169-173
    CrossrefPubMedGoogle Scholar
  • 125 Avis I, Jett M, Kasprzyk P G, Cuttitta F, Treston A M, Maneckjee R, Mulshine J L. Effect of gastrin-releasing peptide on the pancreatic tumor cell line (Capan).  Mol Carcinog. 1993;  8 (4) 214-220
    PubMedGoogle Scholar
  • 126 Saurin J C, Nemoz-Gaillard E, Sordat B, Cuber J C, Coy D H, Abello J, Chayvialle J A. Bombesin stimulates adhesion, spreading, lamellipodia formation, and proliferation in the human colon carcinoma Isrecol cell line.  Cancer Res. 1999;  59 (4) 962-967
    PubMedGoogle Scholar
  • 127 Meijers M, Appel M J, van Garderen Hoetmer A, Lamers C B, Rovati L C, Jansen J B, Woutersen R A. Effects of cholecystokinin and bombesin on development of azaserine-induced pancreatic tumours in rats: modulation by the cholecystokinin receptor antagonist lorglumide.  Carcinogenesis. 1992;  13 (9) 1525-1528
    PubMedGoogle Scholar
  • 128 Ohlsson B, Fredang N, Axelson J. The effect of bombesin, cholecystokinin, gastrin, and their antagonists on proliferation of pancreatic cancer cell lines.  Scand J Gastroenterol. 1999;  34 (12) 1224-1229
    CrossrefPubMedGoogle Scholar
  • 129 Ohlsson B, Fredang N, Axelson J. The effect of bombesin, cholecystokinin, gastrin, and their antagonists on proliferation of pancreatic cancer cell lines.  Scand J Gastroenterol. 1999;  34 (12) 1224-1229
    CrossrefPubMedGoogle Scholar
  • 130 Qin Y, Halmos G, Cai R Z, Szoke B, Ertl T, Schally A V. Bombesin antagonists inhibit in vitro and in vivo growth of human gastric cancer and binding of bombesin to its receptors.  J Cancer Res Clin Oncol. 1994;  120 (9) 519-528
    CrossrefPubMedGoogle Scholar
  • 131 Pinski J, Halmos G, Yano T, Szepeshazi K, Qin Y, Ertl T, Schally A V. Inhibition of growth of MKN45 human gastric carcinoma xenografts in nude mice by treatment with bombesin/gastrin-releasing-peptide antagonist (RC-3095) and somatostatin analogue RC-160.  Int J Cancer. 1994;  57 (4) 574-580
    PubMedGoogle Scholar
  • 132 Radulovic S, Schally A V, Reile H, Halmos G, Szepeshazi K, Groot K, Milovanovic S, Miller G, Yano T. Inhibitory effects of antagonists of bombesin/gastrin releasing peptide (GRP) and somatostatin analog (RC-160) on growth of HT-29 human colon cancers in nude mice.  Acta Oncol. 1994;  33 (6) 693-701
    PubMedGoogle Scholar
  • 133 Qin Y, Ertl T, Cai R Z, Halmos G, Schally A V. Inhibitory effect of bombesin receptor antagonist RC-3095 on the growth of human pancreatic cancer cells in vivo and in vitro.  Cancer Res. 1994;  54 (4) 1035-1041
    PubMedGoogle Scholar
  • 134 Chaudhry A, Carrasquillo J A, Avis I L, Shuke N, Reynolds J C, Bartholomew R, Larson S M, Cuttitta F, Johnson B E, Mulshine J L. Phase I and imaging trial of a monoclonal antibody directed against gastrin-releasing peptide in patients with lung cancer.  Clin Cancer Res. 1999;  5 3385-3393
    PubMedGoogle Scholar
  • 135 Schally A V, Nagy A. Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors.  Eur J Endocrinol. 1999;  141 (1) 1-14
    CrossrefPubMedGoogle Scholar
  • 136 Maoret J J, Pospai D, Rouyer-Fessard C, Couvineau A, Laboisse C, Voisin T, Laburthe M. Neurotensin receptor and its mRNA are expressed in many human colon cancer cell lines but not in normal colonic epithelium: binding studies and RT-PCR experiments.  Biochem Biophys Res Commun. 1994;  203 (1) 465-471
    CrossrefPubMedGoogle Scholar
  • 137 Reubi J C, Waser B, Friess H, Büchler M, Laissue J. Neurotensin receptors: a new marker for human ductal pancreatic adenocarcinoma.  Gut. 1998;  42 546-550
    PubMedGoogle Scholar
  • 138 Wang L, Friess H, Zhu Z, Graber H, Zimmermann A, Korc M, Reubi J C, Büchler M W. Neurotensin receptor-1 mRNA analysis in normal pancreas and pancreatic disease.  Clin Cancer Res. 2000;  6 (2) 566-571
    PubMedGoogle Scholar
  • 139 Yoshinaga K, Evers B M, Izukura M, Parekh D, Uchida T, Townsend C M, Thompson J C. Neurotensin stimulates growth of colon cancer.  Surg Oncol. 1992;  1 (2) 127-134
    CrossrefPubMedGoogle Scholar
  • 140 Sumi S, Evers B M, Townsend C M, Yoshinaga K, Uchida T, Murakami M, Sato K, Ishizuka J, Thompson J C. Comparative effects of neurotensin and neuromedin N on growth of human pancreatic cancer, MIA PaCa-2.  Surg Oncol. 1993;  2 (5) 267-272
    PubMedGoogle Scholar
  • 141 Evers B M, Zhou Z, Dohlen V, Rajaraman S, Thompson J C, Townsend C M. Fetal and neoplastic expression of the neurotensin gene in the human colon.  Ann Surg. 1996;  223 (5) 464-470
    CrossrefPubMedGoogle Scholar
  • 142 Evers B M, Zhou Z, Celano P, Li J. The neurotensin gene is a downstream target for ras activation.  J Clin Invest. 1995;  95 2822-2830
    PubMedGoogle Scholar
  • 143 Yoshinaga K, Evers B M, Izukura M, Parekh D, Uchida T, Townsend C M, Thompson J C. Neurotensin stimulates growth of colon cancer.  Surg Oncol. 1992;  1 (2) 127-134
    CrossrefPubMedGoogle Scholar
  • 144 Sumi S, Evers B M, Townsend C M, Yoshinaga K, Uchida T, Murakami M, Sato K, Ishizuka J, Thompson J C. Comparative effects of neurotensin and neuromedin N on growth of human pancreatic cancer, MIA PaCa-2.  Surg Oncol. 1993;  2 (5) 267-272
    PubMedGoogle Scholar
  • 145 Iwase K, Evers B M, Hellmich M R, Kim H J, Higashide S, Gully D, Thompson J C, Townsend C M. Inhibition of neurotensin-induced pancreatic carcinoma growth by a nonpeptide neurotensin receptor antagonist, SR48692.  Cancer. 1997;  79 (9) 1787-1793
    CrossrefPubMedGoogle Scholar
  • 146 Herzig M C, Chapman W G, Sheridan A, Rake J B, Woynarowski J M. Neurotensin receptor-mediated inhibition of pancreatic cancer cell growth by the neurotensin antagonist SR 48 692.  Anticancer Res. 1999;  19 (1A ) 213-219
    PubMedGoogle Scholar
  • 147 Iwase K, Evers B M, Hellmich M R, Kim H J, Higashide S, Gully D, Townsend C M. Indirect inhibitory effect of a neurotensin receptor antagonist on human colon cancer (LoVo) growth.  Surg Oncol. 1996;  5 (5-6) 245-251
    PubMedGoogle Scholar
  • 148 Reubi J C, Zimmermann A, Jonas S, Waser B, Neuhaus P, Läderach U, Wiedenmann B. Regulatory peptide receptors in human hepatocellular carcinomas.  Gut. 1999;  45 766-774
    PubMedGoogle Scholar
  • 149 Tang C, Biemond I, Offerhaus G J, Verspaget W, Lamers C B. Expression of receptors for gut peptides in human pancreatic adenocarcinoma and tumour-free pancreas.  Br J Cancer. 1997;  75 (10) 1467-1473
    PubMedGoogle Scholar
  • 150 Waschek J A, Richards M L, Bravo D T. Differential expression of VIP/PACAP receptor genes in breast, intestinal, and pancreatic cell lines.  Cancer Letters. 1995;  92 143-149
    CrossrefPubMedGoogle Scholar
  • 151 Reubi J C, Waser B, Schmassmann A, Laissue J A. Receptor autoradiographic evaluation of cholecystokinin, neurotensin, somatostatin and vasoactive intestinal peptide receptors in gastro-intestinal adenocarcinoma samples: where are they really located?.  Int J Cancer. 1999;  81 376-386
    CrossrefPubMedGoogle Scholar
  • 152 Gamet L,Murat J C, Remaury A, Remesy C, Valet P, Paris H, Denis-Pouxviel C. Vasoactive intestinal peptide and forskolin regulate proliferation of the HT29 human colon adenocarcinoma cell line.  J Cell Physiol. 1992;  150 501-509
    CrossrefPubMedGoogle Scholar
  • 153 Lelievre V, Meunier A C, Caigneaux E, Falcon J, Muller J M. Differential expression and function of PACAP and VIP receptors in four human colonic adenocarcinoma cell lines.  Cell Signal. 1998;  10 (1) 13-26
    CrossrefPubMedGoogle Scholar
  • 154 Björk J, Nilsson J, Hultcrantz R, Johansson C. Growth-regulatory effects of sensory neuropeptides, epidermal growth factor, insulin, and somatostatin on the non-transformed intestinal epithelial cell line IEC-6 and the colon cancer cell line HT29.  Scand J Gastroenterol. 1993;  28 879-884
    PubMedGoogle Scholar
  • 155 Ogasawara M, Murata J, Ayukawa K, Saimi I. Differentiatial effect of intestinal neuropeptides on invasion and migration of colon carcinoma cells in vitro.  Cancer Lett. 1997;  116 (1) 111-116
    CrossrefPubMedGoogle Scholar
  • 156 Jiang S, Kopras E, McMichael M, Bell R H, Ulrich C D. Vasoactive intestinal peptide (VIP) stimulates in vitro growth of VIP-1 receptor-bearing human pancreatic adenocarcinoma-derived cells.  Cancer Res. 1997;  57 (8) 1475-1480
    PubMedGoogle Scholar
  • 157 Zia H, Leyton J, Casibang M, Hau V, Brenneman D, Fridkin M, Gozes I, Moody T W. (N-stearyl, norleucine17) VIP hybrid inhibits the growth of pancreatic cancer cell lines.  Life Sci. 2000;  66 (5) 379-387
    PubMedGoogle Scholar
  • 158 Csernus V, Schally A V, Groot K. Antagonistic analogs of growth hormone releasing hormone (GHRH) inhibit cyclic AMP production of human cancer cell lines in vitro.  Peptides. 1999;  20 (7) 843-850
    CrossrefPubMedGoogle Scholar
  • 159 Liu C D, Slice L W, Balasubramaniam A, Walsh J H, Newton T R, Saxton R E, McFadden D W. Y2 receptors decrease human pancreatic cancer growth and intracellular cyclic adenosine monophosphate levels.  Surgery. 1995;  118 (2) 229-235
    PubMedGoogle Scholar
  • 160 Cox H M, Tough I R. Functional characterization of receptors with affinity for PYY, NPY, [Leu31,Pro34]NPY and PP in a human colonic epithelial cell line.  Br J Pharmacol. 1995;  116 (6) 2673-2678
    PubMedGoogle Scholar
  • 161 Liu C D, Balasubramaniam A, Saxton R E, Paiva M, McFadden D W. Human pancreatic cancer growth is inhibited by peptide YY and BIM-43 004-1.  J Surg Res. 1995;  58 (6) 707-712
    CrossrefPubMedGoogle Scholar
  • 162 Liu C D, Rongione A J, Garvey L, Balasubramaniam A, McFadden D W. Adjuvant hormonal treatment with peptide YY or its analog decreases human pancreatic carcinoma growth.  Am J Surg. 1996;  171 (1) 192-196
    CrossrefPubMedGoogle Scholar
  • 163 Heisler T, Towfigh S, Simon N, Liu C, McFadden D W. Peptide YY augments gross inhibition by vitamin E succinate of human pancreatic cancer cell growth.  J Surg Res. 2000;  88 (1) 23-25
    CrossrefPubMedGoogle Scholar
  • 164 Kling K, Kim F, Cole M, McFadden D. B-cell leukemia protein-2 and peptide YY chemotherapy resistance in colon cancer.  Am J Surg. 1999;  178 (5) 411-414
    CrossrefPubMedGoogle Scholar
  • 165 Walsh J H. Gastrointestinal hormones: Past, present, and future.  Gastroenterology. 1993;  104 653-657
    PubMedGoogle Scholar
  • 166 Reubi J C, Krenning E, Lamberts S WJ, Kvols L. In vitro detection of somatostatin receptors in human tumors.  Metabolism. 1992;  41 (Suppl. 2) 104-110
    CrossrefPubMedGoogle Scholar
  • 167 Reubi J C, Laissue J A, Waser B, Horisberger U, Schaer J C. Expression of somatostatin receptors in normal, inflamed, and neoplastic human gastro-intestinal tissues.  Ann NY Acad Sci. 1994;  733 122-137
    PubMedGoogle Scholar
  • 168 Vuaroqueaux V, Dutour A, Briard N, Monges G, Grino M, Oliver C, Ouafik L. No loss of sst receptors gene expression in advanced stages of colorectal cancer.  Eur J Endocrinol. 1999;  140 (4) 362-366
    CrossrefPubMedGoogle Scholar
  • 169 Reubi J C, Zimmermann A, Jonas S, Waser B, Neuhaus P, Läderach U, Wiedenmann B. Regulatory peptide receptors in human hepatocellular carcinomas.  Gut. 1999;  45 766-774
    PubMedGoogle Scholar
  • 170 Tan C K, Podila P V, Taylor J E, Nagorney D M, Wiseman G A, Gores G J, LaRusso N F. Human cholangiocarcinomas express somatostatin receptors and respond to somatostatin with growth inhibition.  Gastroenterology. 1995;  108 (6) 1908-1916
    PubMedGoogle Scholar
  • 171 Liebow C, Reilly C, Serrano M, Schally A V. Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase.  Proc Natl Acad Sci USA. 1989;  86 (6) 2003-2007
    PubMedGoogle Scholar
  • 172 Singh P, Townsend C M, Poston G J, Reubi J C. Specific binding of cholecystokinin, estradiol and somatostatin to human pancreatic cancer xenografts.  J Steroid Biochem Mol Biol. 1991;  39 759-767
    CrossrefPubMedGoogle Scholar
  • 173 Hoyer D, Lubbert H, Bruns C. Molecular pharmacology and somatostatin receptors.  Naunyn Schmiedebergs Arch Pharmacol. 1994;  350 451-453
    PubMedGoogle Scholar
  • 174 Szepeshazi K, Halmos G, Schally A V, Arencibia J M, Groot K, Vadillo-Buenfil M, Rodriguez-Martin E. Growth inhibition of experimental pancreatic cancers and sustained reduction in epidermal growth factor receptors during therapy with hormonal peptide analogs.  J Cancer Res Clin Oncol. 1999;  125 (8-9) 444-452
    CrossrefPubMedGoogle Scholar
  • 175 Vidal C, Rauly I, Zeggari M, Delesque N, Esteve J P, Saint-Laurent N, Vaysee N, Susini C. Up-regulation of somatostatin receptors by epidermal growth factor and gastrin in pancreatic cancer cells.  Mol Pharmacol. 1994;  46 (1) 97-104
    PubMedGoogle Scholar
  • 176 Delesque N, Rauly I, Buscail L. Expression of SSTR2 somatostatin receptor subtype inhibited pancreatic tumor cell growth.  Digestion. 1995;  56 277
    PubMedGoogle Scholar
  • 177 Froidevaux S, Hintermann E, Torok M, Macke H R, Beglinger C, Eberle A N. Differential regulation of somatostatin receptor type 2 (sst 2) expression in AR4-2J tumor cells implanted into mice during octreotide treatment.  Cancer Res. 1999;  59 (15) 3652-3657
    PubMedGoogle Scholar
  • 178 Rochaix P, Delesque N, Esteve J P, Saint-Laurent N, Voight J J, Vaysee N, Susini C, Buscail L. Gene therapy for pancreatic carcinoma: local and distant antitumor effects after somatostatin receptor sst2 gene transfer.  Hum Gene Ther. 1999;  10 (6) 995-1008
    CrossrefPubMedGoogle Scholar
  • 179 Denzler B, Reubi J C. Expression of somatostatin receptors in peritumoral veins of human tumors.  Cancer. 1999;  85 188-198
    CrossrefPubMedGoogle Scholar
  • 180 Lamberts S W, Bakker W H, Reubi J C, Krenning E R. Somatostatin-receptor imaging in the localization of endocrine tumors.  N Engl J Med. 1990;  323 (18) 1246-1249
    CrossrefPubMedGoogle Scholar
  • 181 Krenning E P, Kwekkeboom D J, Reubi J C, van Hagen P M, van Eijek C H, Oei H Y. 111In-octreotide scintigraphy in oncology.  Digestion. 1993;  54 (Suppl. 1) 84-87
    PubMedGoogle Scholar
  • 182 Hurst R D, Modlin I M. Use of radiolabeled somatostatin analogs in the identification and treatment of somatostatin receptor-bearing tumors.  Digestion. 1993;  54 (Suppl. 1) 88-91
    PubMedGoogle Scholar
  • 183 Lamberts S WJ, Reubi J C, Krenning E P. The role of somatostatin analogs in the control of tumor growth.  Seminars in Oncology. 1994;  21 (Suppl. 13) 61-64
    PubMedGoogle Scholar
  • 184 Liebow C, Reilly C, Serrano M, Schally A V. Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase.  Proc Natl Acad Sci USA. 1989;  86 (6) 2003-2007
    PubMedGoogle Scholar
  • 185 Poston G J, Gillespie J, Guillou P J. Biology of pancreatic cancer.  Gut. 1991;  32 800-812
    PubMedGoogle Scholar
  • 186 Szende B, Zalatnai A, Schally A V. Programmed cell death (apoptosis) in pancreatic cancers of hamsters after treatment with analogs of both luteinizing hormone-releasing hormone and somatostatin.  Proc Natl Acad Sci USA. 1989;  86 1643-1647
    PubMedGoogle Scholar
  • 187 Payer J, Huorka M, Duris I, Mickulecky M, Kratochvilova H, Ondrejka P. Somatostatin and large bowel polyps.  Hepatogastroenterol. 1995;  42 (6) 775-777
    PubMedGoogle Scholar
  • 188 Chen T B, Huzak M, Macura S, Vuk-pavlovic S. Somatostatin analogue octreotide modulates metabolism and effects of 5-fluorouracil and 5-fluorouridine in human colon cancer spheroids.  Cancer Lett. 1994;  86 (1) 41-51
    CrossrefPubMedGoogle Scholar
  • 189 Liu X, Zhang Z, Yang L, Qiang O. Regulative effects pentagastrin and somatostatin on growth of human gastric cancer cells in vitro.  Hua Hsi I Ko Ta Hsueh Hsueh Pao. 1998;  29 (3) 292-294
    PubMedGoogle Scholar
  • 190 Diaconu C C, Szathmari M, Keri G, Venetianer A. Apoptosis is induced in both drug-senstive and multidrug-resistant hepatoma cells by somatostatin analogue TT-232.  Brit J Cancer. 1999;  80 (8) 1197-1203
    PubMedGoogle Scholar
  • 191 Saltz L, Trochanowski B, Buckley M. Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors.  Cancer. 1993;  72 244 - 248
    PubMedGoogle Scholar
  • 192 Eriksson B, Oberg K. Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook.  AA Oncol. 1999;  10 (Suppl. 2) S31-S38
    PubMedGoogle Scholar
  • 193 Degen L, Beglinger C. The role of octreotide in the treatment of gastroenteropancreatic endocrine tumors.  Digestion. 1999;  60 (Suppl. 2) 9-14
    PubMedGoogle Scholar
  • 194 Goldberg R M, Moertel C G, Wieand H S, Krook J E, Schutt A J, Veeder M H, Mailliard J A, Dalton R J. A phase III evaluation of a somatostatin analogue (octreotide) in the treatment of patients with asymptomatic advanced colon carcinoma. North Central Cancer Treatment Group and the Mayo Clinic.  Cancer. 1995;  76 (6) 961-966
    PubMedGoogle Scholar
  • 195 Cirillo F, Bottini A, Brunelli A, Zuffada S, Bassi M, Filippini L, Alquati P. Octreotide in the treatment of advanced pancreatic tumor. Preliminary study.  Minerva Chir. 1998;  53 (12) 979-985
    PubMedGoogle Scholar
  • 196 Raderer M, Hejna M H, Kurtaran A, Kornek G V, Valencak J B, Oberhuber G, Vorbeck F, Virgolini I, Scheithauer W. Successful treatment of an advanced hepatocellular carcinoma with the long-acting somatostatin analog lanreotide.  Am J Gastroenterol. 1999;  94 (1) 278-279
    CrossrefPubMedGoogle Scholar
  • 197 Raderer M, Hejna M H, Muller C, Kornek G V, Kurtaran A, Virgolini I, Fiebieger W, Hamilton G, Scheithauer W. Treatment of hepatocellular cancer with the long acting somatostatin analog lanreotide in vitro and in vivo.  Int J Oncol. 2000;  16 (6) 1197-1201
    PubMedGoogle Scholar
  • 198 Kouroumalis E, Skordilis P, Thermos K, Vasilaki A, Moschandrea J, Manousos O N. Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study.  Gut. 1998;  42 (3) 442-447
    CrossrefPubMedGoogle Scholar

1 Diese Arbeit wird von der Sander Stiftung unterstützt.

Christian Lersch

II. Medizinische Klinik und Poliklinik
der Technischen Universität München
Klinikum rechts der Isar

Ismaninger Straße 22

81675 München

Phone: 089-4140-2482

Fax: 089-4140-4968

Email: christian.lersch@lrz.tum.de

      >